9 results about "Benzbromarone" patented technology

The invention relates to the technical field of medicines, in particular to application of benzbromarone in preparation of antithrombotic drugs. The research finds that benzbromarone clinically used for treating hyperuricemia can be combined with HSP47 on platelets to inhibit the interaction between the HSP47 and collagen so as to reduce platelet activation and thrombosis, which prompts that benzbromarone is an HSP47 inhibitor with an anti-platelet effect; benzbromarone has the effects of inhibiting mouse common carotid artery thrombosis and relieving cerebral ischemia reperfusion injury. Experiments finally confirm that benzbromarone can inhibit formation of common carotid artery thrombosis, does not affect the blood coagulation function, is low in cytotoxicity, has the drug effect similar to that of aspirin and clopidogrel which are commonly used at present, and can become an effective and safe therapeutic drug for cerebral arterial thrombosis.

The application discloses application of low-molecular pachyman in preparation of a medicine for simultaneously relieving hyperuricemia and liver and kidney injury, and belongs to the technical field of biological medicine. The application finds through experiments that the low-molecular pachyman has good uric acid lowering effect, and the cytotoxicity result shows that the low-molecular pachyman (0-2000 mu g / mL) has no significant toxicity to liver and kidney cells; meanwhile, the application also finds that the low-molecular pachyman can relieve liver and kidney injury caused by allopurinol and benzbromarone when lowering uric acid. Therefore, the low-molecular pachyman in the application has a good application prospect in relieving hyperuricemia caused by oxypurinol and antagonizing liver and kidney injury caused by drugs.

The invention discloses a new application of benzbromarone or pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. The invention belongs to the technical field of medicine. Experimental results show that the benzbromarone can significantly reduce collagen deposition and inflammatory infiltration in lung tissues, reduce fibrosis area, improve lung functions of patients with pulmonary fibrosis, inhibit lung fibroblast activation and inhibit fibrosis progress. The action mechanism of the gene is related to inhibition of expression of BAG2, FN1, Collagen I and protein. The invention provides a brand new medicine choice for treating pulmonary fibrosis, has the unique advantage of new use of old medicine, and has the potential of short research and development period, known safety and definite curative effect. Meanwhile, the invention further expands the application of benzbromarone in preparation of the protein inhibitor and the in-vitro reagent.

The invention discloses a pharmaceutical composition of benzbromarone and a preparation method thereof, and by optimizing prescription components and a process of a benzbromarone pharmaceutical oral preparation, the provided pharmaceutical composition of benzbromarone or salts thereof is pure white in color, complete and bright in surface and good in dissolution performance. The preparation method of the pharmaceutical composition of the benzbromarone or the salt thereof is simple and convenient, an organic solution containing the benzbromarone or the salt thereof does not need to be prepared, the risk of organic solvent residue does not exist, the granulation process window is large, and industrial production is easy; the particles obtained by the process are uniform, compact and good in flowability; the tablets obtained by the process are pure white in color, complete and bright in surface, small in weight difference and good in dissolution performance.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a supramolecular extraction method of ancarnosine, an efficacy-superposed uric acid-reducing product and application. The supramolecular extraction method of the ancarnosine comprises the following steps: firstly, adding water into tuna muscles, and crushing to obtain homogenate; adding alkaline protease and cyclodextrin into the homogenate, then adding special enzyme for aquatic products and flavourzyme, carrying out enzymolysis, adding a catalyst in batches, and carrying out purification, so as to obtain the product. According to the invention, the synergistic effect among the alkaline protease, the special enzyme for aquatic products and the flavourzyme is catalyzed by the catalyst, supramolecular extraction of the carnosine with high bioavailability and high extraction rate is carried out, and the carnosine and other effective components are mixed by using an embedding technology to obtain the embedding product for reducing uric acid. Animal model tests show that the uric acid reducing effect of the traditional Chinese medicine composition is better than that of western medicines including benzbromarone and allopurinol, and the traditional Chinese medicine composition has the advantages of being simple in formula, obvious in curative effect and free of toxic and side effects.

Described herein are methods for treating or preventing gout or hyperuricemia comprising the administration (3,5-dibromo-4-hydroxyphenyl)(2-(1-hydroxyethyl)benzofuran-3-yl-4,5,6,7-d 4)methanone, and solvates thereof.

The invention discloses a quantitative analysis method for impurity 3, 5-dibromo-4-hydroxybenzoyl chloride in benzbromarone, which comprises the following steps: preparing a test solution, preparing a reference solution, and determining by high performance liquid chromatography-mass spectrometry. According to the present invention, the liquid chromatography-mass spectrometry method is adopted to determine the 3, 5-dibromo-4-hydroxybenzoyl chloride content in the benzbromarone as the direct determination target object, such that the 3, 5-dibromo-4-hydroxybenzoyl chloride in the benzbromarone can be accurately quantified, the result is accurate, and the operation is simple. The analysis method has good precision, accuracy, linearity, specificity, solution stability and durability, and is suitable for quantitative determination of the impurity 3, 5-dibromo-4-hydroxybenzoyl chloride in benzbromarone.

The invention discloses a functional hydrogen water formula capable of promoting uric acid excretion of gout, the functional hydrogen water formula comprises the following components: hydrogen, purified water, sodium bicarbonate, a magnesium ion compound and a vitamin C derivative, the dissolution concentration of the hydrogen in water is 0.8-2.0 mg / L, the addition amount of the sodium bicarbonate is 0.5-3.0 g / L, the concentration of the magnesium ion compound is 10-50 mg / L in terms of magnesium element, the concentration of the vitamin C derivative is 10-50 mg / L in terms of magnesium element, and the concentration of the vitamin C derivative is 0.5-1.0 mg / L. The addition amount of the vitamin C derivative is 0.1-1.0 g / L. The functional hydrogen water can accurately promote uric acid excretion, the serum uric acid (SUA) is reduced by 43.9% (216.3 + / -20.7 [mu] mol / L) compared with a model group and the urinary uric acid (UUA) is increased by 90.7% (238.9 + / -19.8 [mu] mol / 24h) in 24 hours after the functional hydrogen water intervenes in a hyperuricemia rat for 21 days, and the functional hydrogen water is superior to common hydrogen water and can be comparable to benzbromarone. The mechanism is as follows: sodium bicarbonate adjusts the pH value to 7.5-8.5 to help to dissolve urate, magnesium + hydrogen down-regulates URAT1 (reduced by 46.5%), up-regulates GLUT9 (increased by 93.1%) to reduce uric acid reabsorption, and also improves the activity of liver uricase (increased by 61.1%) to assist decomposition, so that a multi-channel excretion promoting system is formed.

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.